Identification of Subtype-Specific Three-Gene Signature for Prognostic Prediction in Diffuse Type Gastric Cancer

Bowen Bao(Hebei University), Xiaofang Che(First Hospital of China Medical University), Chunlei Zheng(First Hospital of China Medical University), Yibo Fan(The University of Texas MD Anderson Cancer Center), Xueying Zheng(University of Maryland, College Park), Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Bowen Yang(Guangzhou University of Chinese Medicine), Yue Jin(Peking University), Xiaojie Zhang(Hangzhou Red Cross Hospital), Kezuo Hou(First Hospital of China Medical University), Xiujuan Qu(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Shitong Yu(Sun Yat-sen University)
Frontiers in Oncology
November 12, 2019
10.3389/fonc.2019.01243
Cited by 18

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417